Potential reasons for improved outcomes at academic centers
| Diagnostics | Improved access to molecular testingMore rapid return of molecular testing results |
| Therapy | Older/comorbid patients more likely to receive antileukemia therapyFaster access to lifesaving drugs (eg, ATRA)Improved access to allogeneic transplantMore clinical trial options |
| Complications | More resources for management of complicationsMultidisciplinary team with expertiseAncillary support staffConsulting specialistsEarly diagnosis of and expertise in managing complications (eg, differentiation syndrome, fungal infections) → decreased early deathStandard operating policies (eg, antimicrobial prophylaxis, line care) |
| Diagnostics | Improved access to molecular testingMore rapid return of molecular testing results |
| Therapy | Older/comorbid patients more likely to receive antileukemia therapyFaster access to lifesaving drugs (eg, ATRA)Improved access to allogeneic transplantMore clinical trial options |
| Complications | More resources for management of complicationsMultidisciplinary team with expertiseAncillary support staffConsulting specialistsEarly diagnosis of and expertise in managing complications (eg, differentiation syndrome, fungal infections) → decreased early deathStandard operating policies (eg, antimicrobial prophylaxis, line care) |
ATRA, all trans retinoic acid; DIC, disseminated intravascular coagulation.